Insights & news

Belgium Eases Conditions for Parallel Imports of Pharmaceuticals

  • 16/09/2022
  • News

Today, 16 September 2022, marks the entry into force of a Royal Decree of 4 September 2022 "amending the Royal Decree of 19 April 2001 on the parallel import of medicines for human use and the parallel distribution of medicines for human and veterinary use" (the RD; see attached copy). The RD was published in the Belgian Official Journal on 15 September 2022.
 
Easing the conditions for obtaining a parallel import licence, the RD removes the condition that the medicinal product for which a parallel import licence is sought must have "the same therapeutic indications" (“dezelfde therapeutische indicaties”/“les mêmes indications thérapeutiques”) as the Belgian reference medicinal product. Following the removal of this condition, it suffices for the parallel importer to demonstrate that:

  1. the imported medicinal product has been granted a marketing authorisation in the EEA state of exportation;
  2. a reference medicinal product exists in Belgium; and
  3. without having to be identical in all respects to the reference medicinal product, the imported medicinal product at least:
    1. has the same qualitative and quantitative composition in active substances;
    2. is therapeutically equivalent; and
    3. has the same pharmaceutical form.  

As follows from the Council of State’s advisory opinion on the draft RD (see attached copy), the “same therapeutic indications" condition was removed because it imposes an additional requirement which is not foreseen by the case law of the Court of Justice of the European Union. More precisely, it would allegedly follow from the Delfarma judgment of 3 July 2019 (Case C-387/18; see, Van Bael & Bellis Life Sciences News and Insights of 5 August 2019) and the kohlpharma II judgment of 8 October 2020 (Case C-602/19; see, Van Bael & Bellis Life Sciences News and Insights of 13 October 2020) that the condition “could qualify as a measure having equivalent effect within the meaning of Article 34 TFEU, which cannot be justified on the basis of Article 36 TFEU”.
 
As the amendment facilitates parallel imports significantly, it will likely lead to an increase in the number of parallel imported products in Belgium.

Key contacts

Related insights

Sign up for updates
    • 15/09/2022
    • News

    Swiss Competition Authority Carries out Dawn Raid in Probe regarding Possible Abuse of Patent Rights

    On Tuesday, the Swiss Competition Authority carried out a dawn raid to collect evidence in a probe regarding a possible abuse of a dominant position in relation to dermatological medication (see, today’s attached press release in three languages). According to press reports, Novartis acknowledged to be the target of the investigation.

    Read more
    • 07/09/2022
    • News

    European Commission Prohibits Acquisition of Grail by Illumina

    On 6 September 2022, the European Commission (the Commission) prohibited the acquisition of cancer detection test start-up Grail by genetic and genomic analysis firm Illumina.

    Read more
    • 02/09/2022
    • News

    European Union Medical Device Coordination Group Publishes List of Action Items

    Back in June 2022, EU Health Ministers expressed concern that innovative medical devices would be delayed in reaching the market and that, generally, the supply of medical devices would be disrupted. In response, the Medical Device Coordination Group (MDCG), an advisory and coordinating body of Member State representatives responsible for administering Regulation (EU) 2017/45 governing medical devices (MDR) and Regulation (EU) 2017/46 governing in vitro diagnostic medical devices (IVDR), produced at the end of August 2022 a list of action items to make the most of the transition periods which both the MDR and the IVDR provide for (see, attached MDCG Position Paper 2022-14). The MDCG stresses that its measures are designed to improve the efficiency of the new regulatory framework, rather than alleviate its requirements, and that they will certainly not be implemented at the expense of the devices’ safety.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *